Tags

Type your tag names separated by a space and hit enter

Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.
Lancet 1983; 2(8356):926-30Lct

Abstract

A case-control study of 314 breast cancer patients aged less than 37 at diagnosis and 314 individually matched controls was done to assess the influence of oral-contraceptive (OC) use on the risk of the disease. Long-term use before age 25 of combination-type OCs with a "high" content of the progestogen component was associated with increased risk of breast cancer: the relative risk was approximately 4 after 5 years of such use, and 9 cases and no controls had used such combination-type OCs for more than 6 years before age 25. Use of combination-type OCs with a "low" progestogen component appears to increase breast-cancer risk little or not at all.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

6138501

Citation

Pike, M C., et al. "Breast Cancer in Young Women and Use of Oral Contraceptives: Possible Modifying Effect of Formulation and Age at Use." Lancet (London, England), vol. 2, no. 8356, 1983, pp. 926-30.
Pike MC, Henderson BE, Krailo MD, et al. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 1983;2(8356):926-30.
Pike, M. C., Henderson, B. E., Krailo, M. D., Duke, A., & Roy, S. (1983). Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet (London, England), 2(8356), pp. 926-30.
Pike MC, et al. Breast Cancer in Young Women and Use of Oral Contraceptives: Possible Modifying Effect of Formulation and Age at Use. Lancet. 1983 Oct 22;2(8356):926-30. PubMed PMID: 6138501.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. AU - Pike,M C, AU - Henderson,B E, AU - Krailo,M D, AU - Duke,A, AU - Roy,S, PY - 1983/10/22/pubmed PY - 1983/10/22/medline PY - 1983/10/22/entrez KW - Age Factors KW - Biology KW - Birth Order KW - Breast Cancer KW - Cancer KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Methods--side effects KW - Control Groups KW - Demographic Factors KW - Diseases KW - Endocrine System KW - Estrogens KW - Family And Household KW - Family Characteristics KW - Family Planning KW - Family Relationships KW - Fertility KW - Fertility Measurements KW - First Birth KW - High Risk Women KW - Hormones KW - Menarche KW - Menopause KW - Neoplasms KW - Oral Contraceptives, Combined KW - Oral Contraceptives--side effects KW - Physiology KW - Population KW - Population Characteristics KW - Population Dynamics KW - Pregnancy History KW - Progestational Hormones KW - Progesterone KW - Reproduction KW - Reproductive Control Agents KW - Research Methodology KW - Time Factors SP - 926 EP - 30 JF - Lancet (London, England) JO - Lancet VL - 2 IS - 8356 N2 - A case-control study of 314 breast cancer patients aged less than 37 at diagnosis and 314 individually matched controls was done to assess the influence of oral-contraceptive (OC) use on the risk of the disease. Long-term use before age 25 of combination-type OCs with a "high" content of the progestogen component was associated with increased risk of breast cancer: the relative risk was approximately 4 after 5 years of such use, and 9 cases and no controls had used such combination-type OCs for more than 6 years before age 25. Use of combination-type OCs with a "low" progestogen component appears to increase breast-cancer risk little or not at all. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/6138501/Breast_cancer_in_young_women_and_use_of_oral_contraceptives:_possible_modifying_effect_of_formulation_and_age_at_use_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(83)90450-6 DB - PRIME DP - Unbound Medicine ER -